北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 眼科  > 期刊论文
学科主题: 临床医学
题名:
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
作者: Wong, Ian Y.1; Shi, Xuan2; Gangwani, Rita1; Zhao, Paul3; Iu, Lawrence P.1; Li, Qing1; Ng, Alex1; Li, Xiaoxin2
关键词: Age related macular degeneration ; Half-dose ; Half-fluence ; Photodynamic therapy ; Polypoidal choroidal vasculopathy ; Ranibizumab ; Verteporfin
刊名: BMC OPHTHALMOLOGY
发表日期: 2015-06-30
DOI: 10.1186/s12886-015-0061-8
卷: 15
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Ophthalmology
研究领域[WOS]: Ophthalmology
关键词[WOS]: CENTRAL SEROUS CHORIORETINOPATHY ; CONTROLLED-TRIAL ; VERTEPORFIN ; FLUENCE ; SAFETY
英文摘要:

Background: To evaluate the efficacy and safety of half-dose photodynamic therapy (PDT combined with ranibizumab for polypoidal choroidal vasculopathy (PCV). PCV is commonly treated with a combination of anti-vascular endothelial growth factor and standard-dose photodynamic therapy (PDT). Choroidal ischemia and visual loss can be resulted from the standard-dose PDT. Half-dose PDT has proved to produce similar results and safety profile in treating central serous chorioretinopathy. Half-dose PDT may offer an alternative for PCV cases where the damage to choroidal vasculature maybe less. Here, we report the efficacy of treating PCV cases with combination of ranibizumab and half-dose PDT.

Methods: In this prospective, non-comparative, interventional case series, 19 treatment-naive eyes were treated with combined half-dose PDT and ranibizumab. All subjects were followed up for 12 months with measurement of best-corrected visual acuity (BCVA), central foveal thickness (CFT) by optical coherence tomography. Indocyanine green angiogram (ICG) was performed every 3-monthly, and subjects assessed in terms of polyp regression rates, changes in vision and central foveal thickness, need to repeat half-dose PDT. Subgroup analysis was performed based on ICG features.

Results: The mean logMAR BCVA improved from 0.64 at baseline to 0.41 at 12 months. The mean CFT improved from 459.6mum at baseline to 384.2mum at 12 months. The difference between baseline BCVA and CFT and that at 12 months were statistically significant (both P = 0.03). Polyp regression rate after one half-dose PDT was 42.1 %. This was 61.5 % in the polyp-only group, while that in the branching-vascular-network (BVN) group was 0 % (P = <0.01).

Conclusion: Half-dose PDT combined with intravitreal ranibizumab was able to induce high polyp regression rate in PCV cases that had one single polyp.

语种: 英语
项目资助者: Novartis Pharmaceuticals (Hong Kong) Limited
WOS记录号: WOS:000357003800001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/62768
Appears in Collections:北京大学第二临床医学院_眼科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Univ Hong Kong, LKS Fac Med, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China
2.Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China
3.Natl Univ Singapore Hosp, Dept Ophthalmol, Singapore, Singapore

Recommended Citation:
Wong, Ian Y.,Shi, Xuan,Gangwani, Rita,et al. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy[J]. BMC OPHTHALMOLOGY,2015,15.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Wong, Ian Y.]'s Articles
[Shi, Xuan]'s Articles
[Gangwani, Rita]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Wong, Ian Y.]‘s Articles
[Shi, Xuan]‘s Articles
[Gangwani, Rita]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace